Logistic regression for STROKE3 case fatality for new cases during follow-up, multiplicative allele effects

Rank SNP name in MORGAM RS-code Chromosome Success Genotype Cases Non-cases Total OR (95% CI) nominal p-value tail-area FDR
1 2Q36_3_MG_433 rs2972147 2 100.0% C/C 7 (23%) 163 (41%) 170 0.538
(0.297, 0.972)		 0.03989 0.79567
C/T 17 (55%) 186 (47%) 203
T/T 7 (23%) 45 (11%) 52
2 SMAD3_MG_431 rs1866317 15 100.0% C/C 2 (6%) 7 (2%) 9 2.109
(1.003, 4.435)		 0.04908 0.79567
C/G 8 (26%) 100 (25%) 108
G/G 21 (68%) 287 (73%) 308
3 MIA3_MG_454 rs3008621 1 98.6% A/A 3 (10%) 8 (2%) 11 1.825
(0.923, 3.608)		 0.08391 0.79567
A/G 10 (33%) 91 (23%) 101
G/G 17 (57%) 290 (75%) 307
4 SMAD3_MG_452 rs17228212 15 99.1% C/C 0 (0%) 22 (6%) 22 0.486
(0.213, 1.108)		 0.08602 0.79567
C/T 9 (30%) 140 (36%) 149
T/T 21 (70%) 229 (59%) 250
5 9P21_3_MG_425 rs1333049 9 100.0% C/C 2 (6%) 77 (20%) 79 0.625
(0.340, 1.149)		 0.13011 0.89433
C/G 16 (52%) 193 (49%) 209
G/G 13 (42%) 124 (31%) 137
6 2Q36_3_MG_461 rs2943634 2 96.2% A/A 7 (23%) 43 (11%) 50 1.550
(0.860, 2.797)		 0.14503 0.89433
A/C 14 (47%) 173 (46%) 187
C/C 9 (30%) 163 (43%) 172
7 9P21_3_MG_420 rs10738610 9 99.3% A/A 13 (42%) 121 (31%) 134 1.499
(0.822, 2.732)		 0.18643 0.95946
A/C 15 (48%) 193 (49%) 208
C/C 3 (10%) 77 (20%) 80
8 SEZ6L_MG_427 rs137209 22 100.0% A/A 4 (13%) 41 (10%) 45 1.398
(0.783, 2.497)		 0.25758 0.95946
A/G 15 (48%) 155 (39%) 170
G/G 12 (39%) 198 (50%) 210
9 FMN2_MG_450 rs1456648 1 98.8% G/G 0 (0%) 13 (3%) 13 0.598
(0.229, 1.557)		 0.29197 0.95946
G/T 6 (20%) 85 (22%) 91
T/T 24 (80%) 292 (75%) 316
10 SEZ6L_MG_444 rs688034 22 99.8% C/C 15 (48%) 223 (57%) 238 0.733
(0.401, 1.341)		 0.31432 0.95946
C/T 13 (42%) 146 (37%) 159
T/T 3 (10%) 24 (6%) 27
11 1Q31_2_MG_453 rs1936982 1 99.1% C/C 6 (20%) 43 (11%) 49 1.372
(0.738, 2.552)		 0.31761 0.95946
C/T 12 (40%) 181 (46%) 193
T/T 12 (40%) 167 (43%) 179
12 SEZ6L_MG_426 rs137205 22 100.0% A/A 3 (10%) 35 (9%) 38 1.338
(0.742, 2.416)		 0.33330 0.95946
A/G 15 (48%) 146 (37%) 161
G/G 13 (42%) 213 (54%) 226
13 5Q21_1_MG_435 rs436495 5 99.1% A/A 3 (10%) 27 (7%) 30 1.316
(0.730, 2.372)		 0.36088 0.95946
A/G 11 (35%) 128 (33%) 139
G/G 17 (55%) 235 (60%) 252
14 PSRC1_MG_460 rs599839 1 99.1% A/A 18 (58%) 224 (57%) 242 0.751
(0.386, 1.460)		 0.39849 0.95946
A/G 11 (35%) 148 (38%) 159
G/G 2 (6%) 18 (5%) 20
15 SEZ6L_MG_442 rs6005015 22 100.0% C/C 3 (10%) 36 (9%) 39 1.238
(0.693, 2.210)		 0.47114 0.95946
C/T 15 (48%) 162 (41%) 177
T/T 13 (42%) 196 (50%) 209
16 MIA3_MG_430 rs17465637 1 99.8% A/A 7 (23%) 29 (7%) 36 1.241
(0.681, 2.263)		 0.48087 0.95946
A/C 6 (19%) 143 (36%) 149
C/C 18 (58%) 221 (56%) 239
17 CELSR2_MG_438 rs4970834 1 100.0% C/C 20 (65%) 248 (63%) 268 0.810
(0.415, 1.580)		 0.53579 0.95946
C/T 9 (29%) 129 (33%) 138
T/T 2 (6%) 17 (4%) 19
18 5Q21_1_MG_455 rs383830 5 99.1% A/A 2 (7%) 21 (5%) 23 1.220
(0.644, 2.310)		 0.54154 0.95946
A/T 10 (33%) 125 (32%) 135
T/T 18 (60%) 245 (63%) 263
19 9P21_3_MG_451 rs1537378 9 99.1% A/A 4 (13%) 50 (13%) 54 1.168
(0.657, 2.074)		 0.59729 0.95946
A/G 16 (53%) 192 (49%) 208
G/G 10 (33%) 149 (38%) 159
20 5Q21_1_MG_436 rs449650 5 99.5% G/G 18 (60%) 246 (63%) 264 0.849
(0.452, 1.593)		 0.60950 0.95946
G/T 10 (33%) 126 (32%) 136
T/T 2 (7%) 21 (5%) 23
21 MTHFD1L_MG_445 rs6922269 6 100.0% A/A 2 (6%) 26 (7%) 28 0.850
(0.441, 1.638)		 0.62763 0.95946
A/G 9 (29%) 126 (32%) 135
G/G 20 (65%) 242 (61%) 262
22 5Q21_1_MG_441 rs565928 5 100.0% C/C 19 (61%) 247 (63%) 266 0.870
(0.464, 1.632)		 0.66468 0.95946
C/T 10 (32%) 126 (32%) 136
T/T 2 (6%) 21 (5%) 23
23 2Q36_3_MG_447 rs7597168 2 100.0% C/C 17 (55%) 224 (57%) 241 1.167
(0.569, 2.390)		 0.67362 0.95946
C/T 13 (42%) 146 (37%) 159
T/T 1 (3%) 24 (6%) 25
24 10Q11_21_MG_428 rs1746048 10 100.0% C/C 23 (74%) 281 (71%) 304 1.181
(0.506, 2.757)		 0.70045 0.95946
C/T 8 (26%) 104 (26%) 112
T/T 0 (0%) 9 (2%) 9
25 10Q11_21_MG_443 rs687175 10 100.0% C/C 0 (0%) 9 (2%) 9 0.847
(0.363, 1.977)		 0.70045 0.95946
C/T 8 (26%) 104 (26%) 112
T/T 23 (74%) 281 (71%) 304
26 10Q11_21_MG_429 rs1746049 10 100.0% C/C 24 (77%) 299 (76%) 323 1.169
(0.481, 2.843)		 0.73099 0.95946
C/T 7 (23%) 89 (23%) 96
T/T 0 (0%) 6 (2%) 6
27 9P21_3_MG_459 rs7865618 9 99.1% A/A 9 (30%) 127 (32%) 136 0.908
(0.519, 1.589)		 0.73602 0.95946
A/G 16 (53%) 200 (51%) 216
G/G 5 (17%) 64 (16%) 69
28 9P21_3_MG_437 rs496892 9 99.8% C/C 7 (23%) 96 (24%) 103 1.100
(0.621, 1.949)		 0.74325 0.95946
C/T 19 (61%) 208 (53%) 227
T/T 5 (16%) 89 (23%) 94
29 10Q11_21_MG_458 rs622472 10 98.6% A/A 22 (73%) 278 (71%) 300 1.135
(0.484, 2.664)		 0.77074 0.95946
A/C 8 (27%) 102 (26%) 110
C/C 0 (0%) 9 (2%) 9
30 10Q11_21_MG_456 rs513391 10 99.1% A/A 22 (73%) 280 (72%) 302 1.131
(0.482, 2.653)		 0.77794 0.95946
A/C 8 (27%) 102 (26%) 110
C/C 0 (0%) 9 (2%) 9
31 10Q11_21_MG_440 rs559580 10 99.8% C/C 0 (0%) 9 (2%) 9 0.911
(0.391, 2.125)		 0.82948 0.96816
C/T 8 (27%) 103 (26%) 111
T/T 22 (73%) 282 (72%) 304
32 19Q12_MG_422 rs11670734 19 100.0% C/C 2 (6%) 36 (9%) 38 1.066
(0.572, 1.986)		 0.84018 0.96816
C/G 15 (48%) 158 (40%) 173
G/G 14 (45%) 200 (51%) 214
33 9P21_3_MG_421 rs10757283 9 99.8% C/C 5 (16%) 103 (26%) 108 0.962
(0.537, 1.721)		 0.89572 0.96816
C/T 21 (68%) 196 (50%) 217
T/T 5 (16%) 94 (24%) 99
34 12Q12_MG_448 rs7970834 12 100.0% G/G 7 (23%) 120 (30%) 127 1.030
(0.570, 1.862)		 0.92151 0.96816
G/T 20 (65%) 195 (49%) 215
T/T 4 (13%) 79 (20%) 83
35 SMAD3_MG_424 rs12913547 15 100.0% C/C 1 (3%) 23 (6%) 24 0.973
(0.486, 1.951)		 0.93926 0.96816
C/T 15 (48%) 168 (43%) 183
T/T 15 (48%) 203 (52%) 218
36 19Q12_MG_446 rs7250581 19 98.6% A/A 0 (0%) 11 (3%) 11 1.026
(0.459, 2.294)		 0.95018 0.96816
A/G 8 (26%) 94 (24%) 102
G/G 23 (74%) 283 (73%) 306
37 10Q11_21_MG_439 rs501120 10 96.9% C/C 0 (0%) 9 (2%) 9 0.983
(0.422, 2.289)		 0.96816 0.96816
C/T 8 (26%) 91 (24%) 99
T/T 23 (74%) 281 (74%) 304

adjusted for: cohort strage3 sex nonhdl hdla bmi bpm dsmoker hisdiab1

Updated on 2008-12-08